Literature DB >> 28505002

Immunohistochemical Classification of Ampullary Carcinomas: Critical Reappraisal Fails to Confirm Prognostic Relevance for Recently Proposed Panels, and Highlights MUC5AC as a Strong Prognosticator.

Yue Xue1, Michelle D Reid, Serdar Balci, Brian Quigley, Takashi Muraki, Bahar Memis, Jun Xia, Ezgi Hacihasanoglu, Gabriela Bedolla, Burcin Pehlivanoglu, Grace E Kim, Takuma Tajiri, Nobuyike Ohike, Ritu Aneja, Alyssa M Krasinskas, Volkan Adsay.   

Abstract

Recently, immunohistochemistry-based classifications of ampullary carcinomas have been proposed (Ang and colleagues [PMID: 24832159]; Chang and colleagues [PMID: 23439753]). In this study, the prognostic value of Ang/Chang panel markers (CK20, MUC1, MUC2, CDX2) as well as other markers (CK7, MUC5AC, and MUC6) were tested on full-faced sections of 136 ampullary carcinoma resections with substantial (>5 mm) invasion. Immunohistochemistry was correlated with both histologic classification (intestinal [INT], pancreatobiliary [PB], or nontubular based on ≥3/5 observer agreement) and clinical outcome. No prognostic correlation was found with MUC1, CDX2, MUC2 or CK20 despite testing with different quantitative cutoffs. CK7 and CK20 were nonspecific. Ang classification had reasonable correlation with histologic subclassification of tubular cases as INT versus PB with high specificity but low sensitivity and ambiguous category was large (29%) and included also some classical cases. Prognostically, Ang classification approached but did not reach statistical significance, even when their large "ambiguous" group was eliminated and only tubular cases were analyzed (Ang-INT vs. Ang-PB; P=0.08). The Chang panel, in which the definition of the INT subcategory is not clearly defined, only marginally reached prognostic significance when tested as MUC1+/CDX2- versus MUC1-/CDX2+ and only by Wilcoxon test (P=0.0485) but 31% of the cases were "unclassifiable." The only individual marker that was found to have direct and strong correlation with the clinical outcome was MUC5AC (not used in the Ang or Chang panels), with statistically significant survival differences found with various cutoffs tested (for 20% cutoff, 5-y survival, 68% vs. 31%; P=0.0002). In addition, MUC5AC significantly stratified the histologically PB and INT cases (P=0.01 and 0.03, respectively), as well as Ang's ambiguous and Chang's unclassified cases (P=0.006 and 0.007, respectively). In conclusion, the widely used putative lineage markers, MUC1/MUC2/CK7/CK20/CDX2, do not seem to have direct/significant prognostic correlation either individually or in combination of Ang and Chang panels. Ang panel is helpful as an adjunct in determining the cell lineage with a few caveats. MUC5AC proves to be a significant independent prognosticator and should be incorporated into evaluation of ampullary carcinomas.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28505002     DOI: 10.1097/PAS.0000000000000863

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma.

Authors:  Sebastian Dwertmann Rico; Franziska Büscheck; David Dum; Andreas M Luebke; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Daniel Perez; Jakob R Izbicki; Michael Neipp; Hamid Mofid; Thies Daniels; Christoph Isbert; Christoph Fraune; Katharina Möller; Anne Menz; Christian Bernreuther; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Ronald Simon; Stefan Steurer; Eike Burandt; Andreas Marx; Till Krech
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

Review 2.  Primary small bowel adenomas and adenocarcinomas-recent advances.

Authors:  Aoife Maguire; Kieran Sheahan
Journal:  Virchows Arch       Date:  2018-07-11       Impact factor: 4.064

3.  Laterally Spreading Adenocarcinoma Involving the Lower Bile Duct and Duodenum Expressing Heterogeneous Immunohistochemical Phenotypes.

Authors:  Katsuyuki Miyabe; Kenji Notohara; Go Asano; Kenta Kachi; Akihisa Kato; Makoto Natsume; Naruomi Jinno; Yasuki Hori; Michihiro Yoshida; Itaru Naitoh; Kazuki Hayashi; Hirotaka Ohara; Satoru Takahashi; Hiromi Kataoka
Journal:  Intern Med       Date:  2019-07-10       Impact factor: 1.271

Review 4.  Prognostic and Clinicopathological Significance of MUC Family Members in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Chao Li; Didi Zuo; Tao Liu; Libin Yin; Chenyao Li; Lei Wang
Journal:  Gastroenterol Res Pract       Date:  2019-12-20       Impact factor: 2.260

5.  Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer.

Authors:  Hyeong Min Park; Sang-Jae Park; Sung-Sik Han; Seong Kweon Hong; Eun Kyung Hong; Sun-Whe Kim
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

Review 6.  Ampullary carcinoma of the duodenum: current clinical issues and genomic overview.

Authors:  Keiichi Okano; Minoru Oshima; Hironobu Suto; Yasuhisa Ando; Eisuke Asano; Hideki Kamada; Hideki Kobara; Tsutomu Masaki; Yasuyuki Suzuki
Journal:  Surg Today       Date:  2021-04-02       Impact factor: 2.549

Review 7.  Ampulla of Vater carcinoma: Molecular landscape and clinical implications.

Authors:  Antonio Pea; Giulio Riva; Riccardo Bernasconi; Elisabetta Sereni; Rita Teresa Lawlor; Aldo Scarpa; Claudio Luchini
Journal:  World J Gastrointest Oncol       Date:  2018-11-15

8.  Prognostic relevance and putative histogenetic role of cytokeratin 7 and MUC5AC expression in Crohn's disease-associated small bowel carcinoma.

Authors:  Giovanni Arpa; Alessandro Vanoli; Federica Grillo; Roberto Fiocca; Catherine Klersy; Daniela Furlan; Fausto Sessa; Sandro Ardizzone; Gianluca Sampietro; Maria Cristina Macciomei; Gabriella Nesi; Francesco Tonelli; Carlo Capella; Giovanni Latella; Antonio Ciardi; Roberto Caronna; Marco Vincenzo Lenti; Rachele Ciccocioppo; Valeria Barresi; Deborah Malvi; Antonietta D'Errico; Fernando Rizzello; Gilberto Poggioli; Claudia Mescoli; Massimo Rugge; Ombretta Luinetti; Marco Paulli; Antonio Di Sabatino; Enrico Solcia
Journal:  Virchows Arch       Date:  2021-05-08       Impact factor: 4.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.